Responses
Regular and young investigator award abstracts
Clinical trials completed
295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas
Compose a Response to This Article
Other responses
No responses have been published for this article.
